“We reinvigorated the generics business in the US,” stated the co-CEOs of Amneal, Chirag Patel and Chintu Patel, as the company’s generics segment saw a 14% jump in its revenue to $342m for quarter ending 31 December 2020. The segment reported operating income of $55m compared to an operating loss of $3m in the prior-year period.
Amneal’s Generics Business Reinvigorated By New Launches
Company Eyes China As A ‘Massive Market’ For Its Generics
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
